Hypoxia and anaemia in patients with cancer of the uterine cervix

Clinical and Translational Oncology

Volumn 7, Issue 8, 2005, Pages 323-331

  Andreu Martínez, Francisco José ^a   Martínez Mateu, Julia M ^a  

^a Hospital Universitari de Sant Joan   (Spain)

Author keywords

Anaemia; Cervix cancer; Erythropoietin; Hypoxia; Radiation therapy

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; ANOXIA; FEMALE; HUMAN; REVIEW; UTERUS CANCER;

ANEMIA; ANOXIA; ERYTHROPOIETIN; FEMALE; HUMANS; UTERINE NEOPLASMS;

EID: 33644878755     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02716547     Document Type: Conference Paper

References (82)

1. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3. DCTD, NCI, NIH, DHHS. March 2003; published December 2003.
2. Ludwig H, van Belle S, Barrett-Lee P, et al. The European cancer anaemia survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-306.
3. Bottini A, Berruti A, Brizzi MP, et al. Pretreatment hemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer. 2003;89:9977-82.
4. Carelle N, Piotto E, Bellanger A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002;95:155-63.
5. Van Belle SJ-P, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol/Hematol. 2003;47:1-11.
6. Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology. 2002;63 Suppl 2:11-8.
7. Shasha D, Harrison LB. Anemia treatment and the radiation oncologist: optimizing patient outcomes. Oncology. 2001;15 (11):1486-91.
8. Pérez Romasanta LA, Calvo Manuel FA, editores. Guía Terapéutica de Soporte en Oncología Radioterápica. Barcelona: Mason; 2004.
9. Escó R, Valencia J Bascón N. Incidencia de anemia en pacientes tratados con radioterapia. En: Laboratorios Esteve, editores. Mesa Redonda sobre Epoetina y Oxigenación Tumoral; 24 de enero 2001; Zaragoza; 2001. p 81-7.
10. Bayo E, Muñoz JL, Errazquin L. Incidencia y prevalencia de anemia en pacientes que reciben radioterapia. Oncologia. 2004;27:525-32.
11. Caro JJ, Salas M, Ward W, et al. Anaemia is an independent prognostic factor for survival in patients with cancer. Cancer. 2001;91:2214-21.
12. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer. 2001;84 Suppl 1:17-23.
13. Harrison LB, Shasha D, White C, et al. Radiotherapy-associated anemia: the scope of the problem. Oncologist. 2000; 5 Suppl 2:1-7.
14. Glaspy J. Anemia and fatigue in cancer patients. Cancer. 2001;92 Suppl:1719-24.
15. Ludwig H, Strasser K. Symptomatology of anemia. Sem Oncol. 2001,28 Suppl 2:7-14.
16. Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. En: Molls M, Vaupel P, editors. Blood perfusion and microenvironment of human tumors. Springer. 2000; p 101-12.
17. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist. 2000;5 Suppl 2:13-8.
18. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther OnKol. 1998;174 Suppl 4: 31-4.
19. Mercadante S, Gebbia V, Marrazzo A, et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26:303-11.
20. Zubiri A, Cuchó T, Abadía MJ. Estadística Oncológica de la Fundación Científica de la Asociación Española Contra el Cáncer. Años 1995 y 1996. Zaragoza: Departamento Nacional de Estadística y Epidemiología de la Fundación Científica de la AECC, 1998.
21. Hagen B, Skjeldestad FE, Halvorsen T, et al. Primary treatment of cervical carcinoma. ten years experience from one Norwegian health region. Acta Obstet Gynecol Scand. 2000;79:1093-9.
22. Coleman MP, Estève J, Damiecki P, et al. Trends in Cancer Incidence and Mortality. IARC Scientific Publications No. 121. Lyon: International Agency for Research on Cancer (IARC); 1993.
23. Raymond L, Ménegoz F, FiorettaG. Recent Trends in incidence of cervical cancer in several regions of southwestern Europe. Rev Epidemiol Sante Publique. 1995;43: 122-6.
24. Vioque J, Fenollar J. Distribución de la mortalidad por cáncer de cérvix en España (1981-1986). Un estudio ecológico. Med Clin. 1995;104:287-92.
25. Miñarro R, Black RJ, Martínez C, et al. Cancer incidence and mortality in Spain. Patterns and trends. IARC Technical Report No 36. Lyon: International Agency for Research on Cancer. (IARC); 2000.
26. Morris NI, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic lymph nodes for high risk cervical cancer: A randomized Radiation Therapy Oncology Group clinical trial. N Engl J Med. 1999;340:1137-43.
27. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-61.
28. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin based chemoradiation in locally advanced cervical cancer. N Engl J Med. 1999;340:1144-53.
29. Whitney CW, Sause W, Bundy BN, et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjuvant to radiation therapy in stages IIBIVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999;17:1339-48.
30. Dueñas-González A, Cetina L, Mariscal I, et al. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003;29:389-99.
31. Reinartz G, Bartsch S, Willich N. Long-term follow-up results of irradiation alone or combined with surgery in stage I-IV carcinoma of the uterine cervix. Zentralbl Gynakol. 2000;122:318-23.
32. Lanciano RM, Pajak TF, Martz K, et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns of care study. Int J Radiat Oncol Biol Phys. 1993;25:391-7.
33. Fyles AW, Pintilie M, Kirkbride P, et al. Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiother Oncol. 1995;35:107-17.
34. Kapp D, Fischer D, Gutierrez E, et al. Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phy. 1983;9:431-55.
35. Kapp KS, Stuecklschweiger GF, Kapp D, et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and Ir-192 High dose rate brachytherapy. Int J Radiat Oncol Biol Phy. 1998;42:531-40.
36. Eifel PJ, Morris M, Wharton JT, et al. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phy. 1994;29:9-16.
37. Eifel PJ, Morris M, Oswald Mj, et al. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases. Cancer. 1990;65:2507-14.
38. Álvarez RD, Soong SJ, Kinney WK, et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol. 1989;35:130-5.
39. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with nodenegative cervix cancer. J Clin Oncol. 2002;20:680-7.
40. Fowler J, Lindstrom M. Loss of local control in radiotherapy. Int J Oncol Biol Phy. 1992;23:457-67.
41. West CM, Davidson SE, Roberts SA, et al. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer. 1997;76:184-90.
42. Kolstad P. Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest. 1968;106:145-57.
43. Höckel M, Schlenger K, Aral, B, et al. Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56: 4509-15.
44. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer. 1998;78: 822-7.
45. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2002;35:71-103.
46. Höckel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic and molecular aspects. J Natl Cancer Inst. 2001;93:266-76.
47. Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001;28 (Suppl 8):36-41.
48. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993;26:45-50.
49. Kainz C, Speiser P, Wanner C, et al. Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Res. 1995;15:1549-52.
50. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995;147:9-19.
51. Bremer GL, Tiebosch ATMG, van der Putten HWHM, et al. Tumor angiogenesis measurement as an independent prognostic parameter in cervical cancer. Am J Obstet Gynecol. 1996;174:126-31.
52. Wiggins DL, Granai CO, Steinhoff MM, et al. Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol. 1995;56:353-6.
53. Sundfor K, Lyng H, Tropé CG, et al. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol. 2000;54:101-7.
54. Evans JC, Bergsjö P. The influence of anaemia on the results of radiotherapy in carcinoma of the cervix. Radiol. 1965;48:709-17.
55. Vigario G, Kurohara SS, George FW. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cancer. Radiol. 1973;106:649-52.
56. Harrison L, Shasha D, Shiaova L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol. 2001;28 Suppl 8:54-9.
57. Bush R. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phy. 1986;12:2047-50.
58. Girinski T, Pejovic-Lenfant MH, Bourhis J, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 38 patients. Int J Radiat Oncol Biol Phy. 1989;16: 37-42.
59. Dische S. Radiotherapy and anaemia- the clinical experience. Radiother Oncol. 1991;20:35-40.
60. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528-36.
61. Obermair A, Cheuk R, Horwood K. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer. 2001; 92:903-8.
62. Bush RS, Jenkin RD, Allt W, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer. 1978;37 Suppl III:302-6.
63. Walker RH. Special report: Transfusion risks. Am J Clin Pathol. 1987;88:374-8.
64. Henry DH. Changing patterns of care in the managament of anemia. Sem Oncol. 1992;16:37-42.
65. Perkins HA. Transfusion induced immunologic unresponsiveness. Trans Med Rev. 1988;2:196-203.
66. Fyles AW, Milosevic M, Pintilie M, et al. Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol. 2000;57:13-9.
67. 2 in cervix carcinoma. Gynecol Oncol. 1997;64:230-6.
68. Pedersen D, Sogarrd H, Overgaard J, et al. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncol. 1995;34:787-95.
69. Henke M, Guttemberg R, Barke A, et al. Erythropoietin for patients undergoing radiotherapy a pilot study. Radiother Oncol. 1999;50:185-90.
70. Thews O, Koening R, Kelleher DK, et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy induced anemia. Br J Cancer. 1998;78:752-6.
71. Lavey RS, Dempsey WH. Erythropoietin increases haemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys. 1993;27:1147-52.
72. Vijayakumar S, Roach M, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labelled, phase II trial. Int J Radiat Oncol Biol Phys. 1993;26 (4):721-9.
73. Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer. 1998;77: 1996-2002.
74. Dusenbery K, McGuire WA, Holt PJ, et al. Erythropoietin increases haemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 1994;29: 1079-84.
75. Antonodou D, Cardamakis E, Sarris G, et al. Effect of the administration of the recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy. Radiother Oncol. 1998;48 Suppl 1. Abstracts ESTRO 483.
76. Lavey RS. Clinical trials experience using erythropoietin during radiation therapy. Strahlenther Onkol. 1998;174 Suppl 4:24-30.
77. Throuvalas NA, Antonadou D, Boufi M, et al. Erythropoietin decreases transfusion requirements during radiochemotherapy. Proc ASCO 2000; 19: 394a (abstract).
78. Throuvalas NA, Antonadou D, Lavey R, et al. Final results of a randomised phase II study evaluating the role of erytrhopoietin during radiochemotherapy for pelvic tumors. Proc ASTRO;60:1071 (abstract).
79. Henke M, Laszig R, Rube C, et al. Erithropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-60.
80. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-14.
81. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erytrhopoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201-16.
82. Machtay M, Pajak T, Suntharalingam M, et al. Definitive radiotherapy ± erithropoietin for squamous cell carcinoma of the head and neck cancer: Preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys. 2004;60 (Suppl 1):132.